tiprankstipranks
Enlivex Therapeutics issued Israeli patent for Allocetra
The Fly

Enlivex Therapeutics issued Israeli patent for Allocetra

Enlivex Therapeutics announced the issuance of an Israeli patent, numbered 284985, entitled, "Combination Immune Therapy and Cytokine Control Therapy for Cancer Treatment." The patent provides added intellectual property protection in Israel into at least 2037, with claims covering the use of for Allocetra for prevention or amelioration of cytokine storms in cancer patients receiving CAR-T therapy, as well as in patients whose cytokine storms result from infectious diseases or non-infectious sources. Oren Hershkovitz, PhD, CEO of Enlivex commented, "We are pleased with the continued buildup of our comprehensive intellectual property portfolio for Allocetra."

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on ENLV:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles